TREATMENT OF PATIENTS WITH DRY AGE-RELATED MACULAR DEGENERATION WITH LUTEIN-CONTAINING VITAMIN-MINERAL COMPLEX: THE OUTCOMES OF ONE-YEAR STUDY
Background: Age-related macular degeneretation is the major cause of blinness in developed world nations.
Aim: to evaluate the clinical effectiveness of Slezavit in the treatment of patients with dry of age-related macular degeneration.
Methods: This was a controlled clinical trial that included 34 patients from the study group and 29 patients from the control group who were examined by visometry, subjective refractometry, direct ophthalmoscopy, optical coherence tomography (OCT) and were interviewed for self-appraisal of their central vision (at the beginning of the study and one year later). The study hold at "Ophthalmic Microsurgery" Hospital, Semey, in the period from 19 December, 2016 to 25 December, 2017.
The statistical data treatment was carried out with the help of SPSS (Statistical Package for the Social Sciences, licenced by Semey Medical University). Proportions, means and standard error (SE) were used for the analysis of quantitative data. The level of statistical significance was preset at р≤0,05.
Results: There was a slight increase in visual acuity in patients from the study group, who consumed one capsule of Slezavit once a day per 3 months. At the same time, there was a slight deterioration in visual acuity of patients in the control group, who did not take any vitamin-mineral complexes. Also, patients from the control group witnessed the ARMD progression, which was manifested as deterioration of the ARMD category. Patients in the "Slezavit" group had a decrease in the thickness of the macula within 3 mm zone, based on OCT, and experienced improvement in the subjective perception of the state of their visual functions compared to the patients from the control group in whom negative dynamics were detected.
Conclusion: prescription of Slezavit to the patients with dry AMD has a beneficial effect on the state of their visual functions, reduction of macula swelling and subjective perception of central vision, compared with the patients who did not take any vitamin-mineral complexes.
Yuliya M. Semenova 1, https://orcid.org/0000-0003-1324-7806
Ulzhan K. Turusbekova 1, Aigerim E. Kairbekova 1, Dinara D. Magauina 1,
Anselm Kampik 2, Anton O. Yurkovskiy 3
1 NCJSC «Semey Medical University», Semey city, Republic of Kazakhstan;
2 Ophthalmology Clinic of the University of Ludwig Maximmilian, Munich, Germany;
3 Novosibirsk State Medical University, student, Novosibirsk city, Russian Federation.
1. Aronow M.E., Chew E.Y. Age-related Eye Disease Study 2: perspectives, recommendations, and unanswered questions // Curr Opin Ophthalmol. 2014. № 25. Р.186-190.
2. Bradley D.T., Zipfel P.F., Hughes A.E. Complement in age-related macular degeneration: a focus on function // Eye. 2011. № 25. Р.683–693.
3. Brown A.C., Amoaku W.M., Dua H.S. Treatment of age-related macular degeneration // J R Soc Med. 2004. № 97. Р.166–169.
4. Buscemi S., Corleo D., Di Pace F.,Petroni M.L., Satriano A., Marchesini G. The Effect of Lutein on Eye and Extra-Eye Health // 2018. doi: 10.3390/nu10091321.
5. Damico F.M., Gasparin F., Scolari M.R, Pedral L.S., Takahashi B.S. New approaches and potential treatments for dry age-related macular degeneration // Arq Bras Oftalmol. 2012. №75(1). Р.71–76.
6. Hogg R.E., Chakravarthy U. Visual function and dysfunction in early and late age-related maculopathy // Prog. Retin Eye Res. 2006. №25. Р.249-76.
7. Landrum J.T., Bone R.A., Joa H., Kilburn M.D., Moore L.L., Sprague K.E. A one-year study of the macular pigment: the effect of 140 days of a lutein supplement // Exp Eye Res. 1997. № 65. Р.57-62.
8. Capogna L., Pelletier M.B. Age-Related Eye Disease Study 2 (AREDS2) // Optometry. 2013 Available at: http://HYPERLINK "http://hyperlink%20%22http//www.allaboutvision.com/nutrition/lutein.htm%22www.allaboutvision.com/nutrition/lutein.htm"www.allaboutvision.com/nutrition/lutein.htm
9. Ma L., Dou H.L., Huang Y.M. Еt al. Improvement of retinal function in early age-related macular degeneration after lutein and zeaxanthin supplementation: a randomized, double-masked, placebo-controlled trial // Am. J. Ophthalmol. 2012. № 154. Р.625–634.
10. McBee W.L., Lindblad A.S., Ferris F.L. Who should receive oral supplement treatment for age-related macular degeneration? // Cochrane Database Syst Rev. 2017. 7:CD000254.
11. Mullins R.F., Russell S.R., Anderson D.H., Hageman G.S. Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease // FASEBJ. 2000. №14. Р. 835–846.
12. Parisi V., Tedeschi M., Gallinaro G., Varano M., Saviano S., Piermarocchi S. Carotenoids and antioxidants in age-related maculopathy italian study: multifocal electroretinogram modifications after 1 year // Ophthalmology. 2008. №115(7). Р.324-333.
13. Rosenfeld P.J., Brown D.M., Heier J.S. Еt al. Ranibizumab for neovascular age-related macular degeneration // N Engl J. Med. 2006. №355(14). Р. 1419–1431.
14. Schmier J.K., Covert D.W., Lau E.C. Patterns and costs associated with progression of age-related macular degeneration // Am. J. Ophthalmol. 2012. №154. Р.675–681.
15. Souied E.H., Delcourt C., Querques G. Еt al. Oral Docosahexaenoic acid in the prevention of exudative age-related macular degeneration: the nutritional AMD Treatment 2 Study. Ophthalmology. 2013. doi:10.1016/j.ophtha.
16. Baiyrkhanova A., Ismailova A., Botabekova T., Enin E., Semenova Y. Crosslinked Chitosan / PVA film, suturated with 5-Fluorouracil for the prevention of proliferative vitreoretinopathy // Internal Journal of Drug Delivery Technology. 2016. №2(6). P. 561-574
17. Wong P., Markey M., Rapp C.M., Darrow R.M., Ziesel A., Organisciak D.T. Enhancing the efficacy of AREDS antioxidants in light-induced retinal degeneration // Mol Vis. 2017. №10. Р.718-739.
18. Wong W.T., Kam W., Cunningham D. Treatment of geographic atrophy by the topical administration of OT-551: results of a phase II clinical trial // Invest Ophthalmol Vis Sci. 2010. №51(12). Р.6131–6139.
Number of Views: 275
Category of articles:
Original articles
Bibliography link
Semenova Yu.M., Turusbekova U.K., Kairbekova A.E., Magauina D.D., Kampik Anselm, Yurkovskiy A.O. Treatment of patients with dry age-related macular degeneration with lutein-containing vitamin-mineral complex: the outcomes of one-year study // Nauka i Zdravookhranenie [Science & Healthcare]. 2020, (Vol.22) 1, pp. 80-87. doi:10.34689/SH.2020.22.1.009Related publications:
ANALYSIS OF CLINICAL AND DEMOGRAPHIC INDICATORS OF PATIENTS WITH PARKINSON'S DISEASE IN THE SOUTHERN REGION OF KAZAKHSTAN
A COMPARATIVE STUDY OF DRUG POLICY REGARDING ORPHAN DISEASES IN THE USA, THE EUROPEAN UNION, AND THE REPUBLIC OF KAZAKHSTAN
MUTATIONS IN CARDIAC ION CHANNEL GENES IN KAZAKHSTANI PATIENTS WITH LONG QT SYNDROME
GENETIC FEATURES OF CONGENITAL DYSFUNCTION OF THE ADRENAL CORTEX CAUSED BY 21-HYDROXYLASE DEFICIENCY IN PERSONS OF KAZAKH NATIONALITY
NON-MOTOR SYMPTOMS IN PARKINSON'S DISEASE USING THE EXAMPLE OF AKTOBE PATIENTS